![Fouzia Laghrissi-Thodes](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Fouzia Laghrissi-Thodes
Directeur/Membre du Conseil chez
MINERVA NEUROSCIENCES, INC.
Fortune : - $ au 31/05/2026
Profil
Dr. Fouzia Laghrissi-Thodes, MD, is a Chief Executive Officer & Director at DalCor Pharmaceuticals Canada, Inc., an Independent Director at Minerva Neurosciences, Inc. and an Independent Director at Smart Immune SAS. She is on the Board of Directors at DalCor Pharmaceuticals Canada, Inc., Minerva Neurosciences, Inc., Cellaïon SA and Smart Immune SAS. Dr. Laghrissi-Thodes was previously employed as a VP-Cardiovascular & Metabolism Therapy by AstraZeneca PLC and a Chief Executive Officer by ZS Pharma, Inc. She also served on the board at Nuro Corp.
She received her doctorate degree from Université François-Rabelais de Tours.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 03/06/2026 | 0 ( -.--% ) | - $ | 31/05/2026 |
Postes actifs de Fouzia Laghrissi-Thodes
| Sociétés | Poste | Début |
|---|---|---|
| MINERVA NEUROSCIENCES, INC. | Directeur/Membre du Conseil | 18/05/2015 |
DalCor Pharmaceuticals Canada, Inc.
 DalCor Pharmaceuticals Canada, Inc. Pharmaceuticals: MajorHealth Technology Develops precision treatments for cardiovascular disease | Directeur Général | 03/04/2018 |
Smart Immune SAS
 Smart Immune SAS BiotechnologyHealth Technology Develops T-cell progenitor-based cell and gene therapy | Directeur/Membre du Conseil | - |
Promethera Therapeutics SA
 Promethera Therapeutics SA Pharmaceuticals: OtherHealth Technology Provides cell therapies for treatment of liver diseases | Directeur/Membre du Conseil | - |
Anciens postes connus de Fouzia Laghrissi-Thodes
| Sociétés | Poste | Fin |
|---|---|---|
| ZS PHARMA INC | Directeur Général | - |
Nuro Corp.
 Nuro Corp. Packaged SoftwareTechnology Services Develops neurological communication software solutions | Directeur/Membre du Conseil | - |
| ASTRAZENECA PLC | Corporate Officer/Principal | - |
Formation de Fouzia Laghrissi-Thodes
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
22
Relations au 1er degré
8
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 8 |
|---|---|
AstraZeneca PLC
 AstraZeneca PLC Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
ZS Pharma, Inc.
 ZS Pharma, Inc. BiotechnologyHealth Technology Develops develop new treatments of kidney and liver diseases | Health Technology |
Université François-Rabelais de Tours
 Université François-Rabelais de Tours Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Minerva Neurosciences, Inc.
 Minerva Neurosciences, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that develops and commercializes drugs to treat patients suffering from central nervous system diseases | Health Technology |
DalCor Pharmaceuticals Canada, Inc.
DalCor Pharmaceuticals Canada, Inc. Pharmaceuticals: MajorHealth Technology Develops precision treatments for cardiovascular disease | Health Technology |
Nuro Corp.
Nuro Corp. Packaged SoftwareTechnology Services Develops neurological communication software solutions | Technology Services |
Smart Immune SAS
Smart Immune SAS BiotechnologyHealth Technology Develops T-cell progenitor-based cell and gene therapy | Health Technology |
Promethera Therapeutics SA
Promethera Therapeutics SA Pharmaceuticals: OtherHealth Technology Provides cell therapies for treatment of liver diseases | Health Technology |
